CN109965270A - 一种降血压专用型临床营养配方及其制备方法 - Google Patents
一种降血压专用型临床营养配方及其制备方法 Download PDFInfo
- Publication number
- CN109965270A CN109965270A CN201910267304.7A CN201910267304A CN109965270A CN 109965270 A CN109965270 A CN 109965270A CN 201910267304 A CN201910267304 A CN 201910267304A CN 109965270 A CN109965270 A CN 109965270A
- Authority
- CN
- China
- Prior art keywords
- parts
- blood pressure
- powder
- calcium
- pressure lowering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000036772 blood pressure Effects 0.000 title claims abstract description 47
- 230000035764 nutrition Effects 0.000 title claims abstract description 29
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000009472 formulation Methods 0.000 title claims description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 20
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 18
- 239000011734 sodium Substances 0.000 claims abstract description 18
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 18
- 230000035622 drinking Effects 0.000 claims abstract description 17
- 235000008216 herbs Nutrition 0.000 claims abstract description 17
- 230000010354 integration Effects 0.000 claims abstract description 17
- 235000015097 nutrients Nutrition 0.000 claims abstract description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000011575 calcium Substances 0.000 claims abstract description 14
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 14
- 235000001465 calcium Nutrition 0.000 claims abstract description 14
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 13
- 235000005911 diet Nutrition 0.000 claims abstract description 12
- 230000037213 diet Effects 0.000 claims abstract description 12
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000011701 zinc Substances 0.000 claims abstract description 12
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 12
- 235000016804 zinc Nutrition 0.000 claims abstract description 12
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 10
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 10
- 239000011718 vitamin C Substances 0.000 claims abstract description 10
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 9
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004615 ingredient Substances 0.000 claims abstract description 9
- 229940046009 vitamin E Drugs 0.000 claims abstract description 9
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 9
- 239000011709 vitamin E Substances 0.000 claims abstract description 9
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052742 iron Inorganic materials 0.000 claims abstract description 7
- 239000011777 magnesium Substances 0.000 claims abstract description 7
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 7
- 239000011574 phosphorus Substances 0.000 claims abstract description 7
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 7
- 229920001503 Glucan Polymers 0.000 claims abstract description 6
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims abstract description 6
- -1 nicotinoyl Chemical group 0.000 claims abstract description 6
- 229960003080 taurine Drugs 0.000 claims abstract description 6
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 5
- 239000011648 beta-carotene Substances 0.000 claims abstract description 5
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 5
- 229960002747 betacarotene Drugs 0.000 claims abstract description 5
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 48
- 239000003094 microcapsule Substances 0.000 claims description 20
- 235000015424 sodium Nutrition 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 229960005069 calcium Drugs 0.000 claims description 13
- 235000019197 fats Nutrition 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 239000003921 oil Substances 0.000 claims description 10
- 235000019198 oils Nutrition 0.000 claims description 10
- 240000008042 Zea mays Species 0.000 claims description 9
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- 229920002774 Maltodextrin Polymers 0.000 claims description 8
- 239000005913 Maltodextrin Substances 0.000 claims description 8
- 229940035034 maltodextrin Drugs 0.000 claims description 8
- 244000068988 Glycine max Species 0.000 claims description 7
- 235000010469 Glycine max Nutrition 0.000 claims description 7
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 7
- 235000005822 corn Nutrition 0.000 claims description 7
- 235000018102 proteins Nutrition 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 102000004407 Lactalbumin Human genes 0.000 claims description 6
- 108090000942 Lactalbumin Proteins 0.000 claims description 6
- 108010038807 Oligopeptides Proteins 0.000 claims description 6
- 102000015636 Oligopeptides Human genes 0.000 claims description 6
- 235000004347 Perilla Nutrition 0.000 claims description 6
- 244000124853 Perilla frutescens Species 0.000 claims description 6
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 6
- 239000004006 olive oil Substances 0.000 claims description 6
- 235000008390 olive oil Nutrition 0.000 claims description 6
- 229960000984 tocofersolan Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical group OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 6
- 244000000626 Daucus carota Species 0.000 claims description 5
- 235000002767 Daucus carota Nutrition 0.000 claims description 5
- 229920001202 Inulin Polymers 0.000 claims description 5
- 240000002853 Nelumbo nucifera Species 0.000 claims description 5
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 5
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 5
- 108010073771 Soybean Proteins Proteins 0.000 claims description 5
- 244000300264 Spinacia oleracea Species 0.000 claims description 5
- 235000009337 Spinacia oleracea Nutrition 0.000 claims description 5
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 5
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 5
- 239000001354 calcium citrate Substances 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 5
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 5
- 229940029339 inulin Drugs 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 235000019710 soybean protein Nutrition 0.000 claims description 5
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 5
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 5
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 235000008939 whole milk Nutrition 0.000 claims description 5
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 4
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 4
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 4
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 4
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 4
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 4
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 4
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 4
- 240000000171 Crataegus monogyna Species 0.000 claims description 4
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 4
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 4
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 4
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 claims description 4
- 239000011627 DL-alpha-tocopherol Substances 0.000 claims description 4
- 240000003183 Manihot esculenta Species 0.000 claims description 4
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims description 4
- 240000000249 Morus alba Species 0.000 claims description 4
- 235000008708 Morus alba Nutrition 0.000 claims description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- 241000124033 Salix Species 0.000 claims description 4
- 241000219784 Sophora Species 0.000 claims description 4
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 4
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 210000003022 colostrum Anatomy 0.000 claims description 4
- 235000021277 colostrum Nutrition 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 235000013312 flour Nutrition 0.000 claims description 4
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- 235000012054 meals Nutrition 0.000 claims description 4
- 239000011435 rock Substances 0.000 claims description 4
- 229940042585 tocopherol acetate Drugs 0.000 claims description 4
- 239000011670 zinc gluconate Substances 0.000 claims description 4
- 235000011478 zinc gluconate Nutrition 0.000 claims description 4
- 229960000306 zinc gluconate Drugs 0.000 claims description 4
- 244000246386 Mentha pulegium Species 0.000 claims description 3
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 3
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 3
- 235000021307 Triticum Nutrition 0.000 claims description 3
- 244000098338 Triticum aestivum Species 0.000 claims description 3
- 102000007544 Whey Proteins Human genes 0.000 claims description 3
- 108010046377 Whey Proteins Proteins 0.000 claims description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 3
- 239000004222 ferrous gluconate Substances 0.000 claims description 3
- 235000013924 ferrous gluconate Nutrition 0.000 claims description 3
- 229960001645 ferrous gluconate Drugs 0.000 claims description 3
- 235000001050 hortel pimenta Nutrition 0.000 claims description 3
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 235000011083 sodium citrates Nutrition 0.000 claims description 3
- 235000021119 whey protein Nutrition 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 2
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 235000019498 Walnut oil Nutrition 0.000 claims description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 2
- 229940114079 arachidonic acid Drugs 0.000 claims description 2
- 235000021342 arachidonic acid Nutrition 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 239000010495 camellia oil Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 239000004519 grease Substances 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 235000009973 maize Nutrition 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 2
- 239000008170 walnut oil Substances 0.000 claims description 2
- 239000011746 zinc citrate Substances 0.000 claims description 2
- 235000006076 zinc citrate Nutrition 0.000 claims description 2
- 229940068475 zinc citrate Drugs 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- 229960001296 zinc oxide Drugs 0.000 claims description 2
- 235000014692 zinc oxide Nutrition 0.000 claims description 2
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 2
- 239000002076 α-tocopherol Substances 0.000 claims description 2
- 235000004835 α-tocopherol Nutrition 0.000 claims description 2
- 229960004256 calcium citrate Drugs 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 240000006240 Linum usitatissimum Species 0.000 claims 1
- 235000004431 Linum usitatissimum Nutrition 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 235000019486 Sunflower oil Nutrition 0.000 claims 1
- 239000004227 calcium gluconate Substances 0.000 claims 1
- 235000013927 calcium gluconate Nutrition 0.000 claims 1
- 229960004494 calcium gluconate Drugs 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 235000004426 flaxseed Nutrition 0.000 claims 1
- 229960003390 magnesium sulfate Drugs 0.000 claims 1
- 229960001790 sodium citrate Drugs 0.000 claims 1
- 239000002600 sunflower oil Substances 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 abstract description 49
- 230000001631 hypertensive effect Effects 0.000 abstract description 19
- 230000001228 trophic effect Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 230000001151 other effect Effects 0.000 abstract description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 8
- 208000006011 Stroke Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 229940091250 magnesium supplement Drugs 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000035487 diastolic blood pressure Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 208000007530 Essential hypertension Diseases 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 235000013675 iodine Nutrition 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000209763 Avena sativa Species 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000016998 Conn syndrome Diseases 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- NEEHYRZPVYRGPP-IYEMJOQQSA-L calcium gluconate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEEHYRZPVYRGPP-IYEMJOQQSA-L 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000037198 cardiovascular physiology Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940029982 garlic powder Drugs 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229960002358 iodine Drugs 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010503 organ complication Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000013846 primary aldosteronism Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000015330 renal sodium excretion Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000021023 sodium intake Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明涉及一种降血压专用型临床营养配方，其包括：蛋白质14‑35份、脂肪2‑9份、碳水化合物50‑60份、膳食纤维4‑10份、牛磺酸0.05‑0.14份、钠0.10‑0.16份、磷0.1‑0.3份、镁0.08‑0.3份、钙0.3‑0.5份、铁0.008‑0.02份、锌0.005‑0.01份、β‑胡萝卜素0.005‑0.04份、维生素E 0.005‑0.04份、维生素C 0.05‑0.4份、烟酰0.005‑0.04份、左旋肉碱0.4‑0.8份、燕麦β‑葡聚糖0.1‑0.8份、膳食精华1～3.5份、药食同源成分0.5～2份和新食品原料0.05‑0.3份；本发明还涉及上述临床营养配方的制备方法。本发明基于高血压患者的营养摄入，对各组分的配比进行适应性调整，同时添加具有降血压、增强抵抗力等功效的药食同源成分、膳食精华和新资源食品等特殊营养素，改善高血压患者营养结构，辅助改善高血压患者的血压状态及机体健康状况，实现降低血压的目的。
Description
技术领域
本发明涉及特殊医学用途配方食品领域，具体涉及一种降血压专用型临床营养配方及其制备方法。
背景技术
高血压是指静息时收缩压或(和)舒张压的持续升高(收缩压≥140mmHg，舒张压≥90mmHg)。病因不明且不可能是单一影响因素的高血压(原发性高血压)比较常见，影响因素包括平滑肌细胞肌膜的离子泵功能障碍、遗传、环境和膳食。以特定病因所致的高血压(继发性高血压)通常由于慢性肾病或原发性醛固酮增多症。在高血压早期不出现病理变化。严重的或长期高血压损害靶器官，主要是心血管系统、脑和肾脏，增加疾病风险包括冠状动脉疾病及心肌梗塞、心脏衰竭、卒中(特别是出血性)、肾衰竭和死亡。
在靶器官并发症产生之前，高血压通常不引起症状。严重的高血压(高血压急症)可引起严重的心血管、神经、肾和视网膜症状。高血压监测是通过多次测量血压可做出高血压的诊断。
高血压是一种以动脉压升高为特征最常见的慢性疾病，也是心脑血管病最主要的危险因素，其脑卒中、心肌梗死、心力衰竭及慢性肾脏病等主要并发症。我国人群监测数据显示，心脑血管死亡占总死亡人数的40％以上，其中高血压是首位危险因素，每年300万心血管死亡中至少一半与高血压有关。人群监测数据还显示，脑卒中的年发病率为250/10万，冠心病事件的年发病率为50/10万，脑卒中发病率是冠心病事件发病率的5倍。在临床治疗试验中，脑卒中/心肌梗死发病比值，在我国高血压人群约5～8：1，而在西方高血压人群约1：1。高血压不仅具有高发病率、高致残率以及高病死率的特点，而且严重消耗医疗和社会资源，给家庭和国家造成沉重负担。
当前我国人群高血压患病率仍呈增长态势，每5个成人中就有1人患高血压。估计目前全国高血压患者至少2亿，约占全球高血压人数的1/5。但是，我国人群高血压患者的知晓率、治疗率和控制率与发达国家相比仍非常低，分别低于 50％、40％和10％。特别是经济文化发展水平较低的农村或边远地区情况尤为严重。脑卒中死亡率在农村地区已超过城市。目前我国约有1.3亿高血压患者不知道自己患有高血压；在已知自己患有高血压的人群中，约有3千万没有治疗；在接受降压治疗的患者中，有75％血压没有达到控制水平。
在我国高血压人群中，绝大多数是轻、中度高血压(占90％)，轻度高血压占60％以上。目前，高血压出现的人群越来越广泛，包括老年人、儿童、青少年、妊娠妇女和中青年人群。血压正常高值水平人群占总成年人群的比例不断增长，尤其是中青年，已经从1991年的29％增加到2002年的34％，是我国高血压患病率持续升高和患病人数剧增的主要来源。估计我国每年新增高血压患者1000 万人。因此，我们面临的高血压防治任务仍十分艰巨。
由于影响高血压发病因素较复杂，现在给予的主要治疗方式是口服降压药物，包括钙通道阻滞剂、血管紧张素转换酶抑制剂(ACEI)、血管紧张素受体阻滞剂(ARB)、利尿剂和β受体阻滞剂五类。但是长期使用药物容易产生依赖性，且会引发不良反应，而且降血压要遵循有效、平稳，血压波动太大可能导致心、脑、肾的供血不足而产生严重后果。
因此，开发一种适用于高血压患者以改善其营养结构从而控制血压的营养配方是十分必要的。
发明内容
本发明的目的在于克服现有技术中的缺陷，针对高血压患者饮食结构不合理、营养不均匀等不良现状，提供一种降血压专用型临床营养配方，通过膳食调控，合理搭配碳水化合物、蛋白质、脂肪的供给能量比值，选择多种维生素、矿物质、药食同源和新资源食品，来改善高血压患者营养结构，辅助改善高血压患者的血压状态及机体健康状况，实现降低血压的目的。
为实现上述目的，本发明采用如下技术方案：
本发明的第一个目的是提供一种降血压专用型临床营养配方，其包括如下组分及其重量份数：蛋白质14-35份、脂肪2-9份、碳水化合物50-60份、膳食纤维4-10份、牛磺酸0.05-0.14份、钠0.10-0.16份、磷0.1-0.3份、镁0.08-0.3份、钙0.3-0.5份、铁0.008-0.02份、锌0.005-0.01份、β-胡萝卜素0.005-0.04份、维生素E 0.005-0.04份、维生素C 0.05-0.4份、烟酰0.005-0.04份、左旋肉碱0.4-0.8 份、燕麦β-葡聚糖0.1-0.8份、膳食精华1～3.5份、药食同源成分0.5～2份和新食品原料0.05-0.3份。
为了进一步优化上述临床营养配方，本发明所采取的技术措施还包括：
进一步地，在上述营养配方中，包括：维生素A 0.0003-0.0008份、维生素D0.000001-0.0000015份、维生素E 0.005-0.01份、维生素B1 0.0008-0.002份、维生素B20.0008-0.002份、维生素B6 0.0008-0.002份、维生素B12 0.000001-0.000004 份、维生素C0.07-0.3份、烟酸0.008-0.03份、叶酸0.0001-0.0003份、泛酸 0.001-0.004份。
进一步地，所述蛋白质选自水解乳清蛋白粉、浓缩乳清蛋白粉、大豆分离蛋白、全蛋粉、牛初乳粉、全脂奶粉、白蛋白肽、大豆肽、海洋鱼低聚肽、小麦低聚肽、玉米低聚肽粉、α-乳清蛋白粉、乳铁蛋白中的至少一种。更优选为包括乳清蛋白、大豆分离蛋白、全脂奶粉、全蛋粉、牛初乳，所述乳清蛋白为水解乳清蛋白粉和/或浓缩乳清蛋白粉。
进一步地，所述脂肪包括饱和脂肪酸、多不饱和脂肪酸、单不饱和脂肪酸、 OPO结构脂、DHA、EPA、ARA、磷脂中的至少一种，更具体地说所述脂肪包括橄榄油微囊粉、紫苏油微囊粉、二十二碳六烯酸油脂、花生四烯酸油脂、鱼油微囊粉、亚麻籽油微囊粉、中链甘油三酯粉、大豆油微囊粉、玉米胚芽油微囊粉、菜籽油微囊粉、核桃油微囊粉、茶油微囊粉、葵花籽油微囊粉中的至少一种；更优选为紫苏油、橄榄油，两者均以微囊粉的形式进行添加。
进一步地，所述碳水化合物包括果糖、冰糖、乳糖、麦芽糊精、木薯淀粉、抗性淀粉中的至少一种；更优选为冰糖、麦芽糊精和木薯淀粉。
进一步地，所述膳食纤维包含菊粉、聚葡萄糖、低聚半乳糖、低聚果糖、低聚木糖、低聚异麦芽糖、抗性糊精、大豆纤维中的至少一种；更优选地，所述膳食纤维包括菊粉、低聚半乳糖、低聚异麦芽糖、抗性糊精和大豆纤维。
进一步地，所述常量元素选自钠、磷、镁、钙、钾中的至少一种；其中钙以碳酸钙、葡萄糖酸钙、柠檬酸钙、乳酸钙、L-乳酸钙、磷酸氢钙、磷酸钙中的任一种或几种形式添加；镁以硫酸镁、葡萄糖酸镁中的任一种或几种形式添加；磷以磷酸氢钙的形式添加；钠以柠檬酸钠的形式添加，钾以葡萄糖酸钾的形式添加。更优选为：钠、磷、镁、钙，具体为：柠檬酸钙、L-乳酸钙、磷酸氢钙、柠檬酸钠、硫酸镁。
进一步地，所述微量元素选自铁、锌、碘、铜、锰中的至少一种，其中铁以葡萄糖酸亚铁的形式添加，锌以葡萄糖酸锌、氧化锌、柠檬酸锌中的任一种或几种形式添加，碘以碘化钾的形式添加，铜以葡萄糖酸铜的形式添加，锰以硫酸锰的形式添加，更优选为：铁和锌，具体为葡萄糖酸亚铁、葡萄糖酸锌。
进一步地，所述维生素C选自L-抗坏血酸、L-抗坏血酸钠中的至少一种。更优选为L-抗坏血酸钠。
进一步地，所述维生素E选自d-α-生育酚、dl-α-生育酚、d-α-醋酸生育酚和 dl-α-醋酸生育酚中的至少一种。更优选为dl-α-生育酚。
进一步地，维生素D选自胆钙化醇、麦角钙化醇中的至少一种。
进一步地，所述膳食精华选自燕麦、荞麦、玉米、糙米、胡萝卜、菠菜、大蒜粉、海带粉、凤梨酵素粉、香菇提取物中的至少一种；更优选为玉米粉、燕麦粉、胡萝卜粉、菠菜粉。
进一步地，所述药食同源成分包括薄荷、荷叶、槐米、菊花、山楂、桑叶。
进一步地，所述新食品原料包括青钱柳叶。
进一步地，所述营养配方中还可添加γ－氨基丁酸。
进一步地，所述脂肪中，不饱和脂肪酸n-6：n-3＝4～6：1。
进一步地，所述营养配方为肠内营养制剂，每100g的总能量为1400-1800kJ。
进一步地，所述营养配方包括乳清蛋白、大豆分离蛋白、全脂奶粉、全蛋粉、牛初乳、牛磺酸、紫苏油、橄榄油、冰糖、麦芽糊精、木薯淀粉、菊粉、低聚半乳糖、低聚异麦芽糖、抗性糊精、大豆纤维、柠檬酸钙、L-乳酸钙、磷酸氢钙、柠檬酸钠、硫酸镁、葡萄糖酸亚铁、葡萄糖酸锌、β-胡萝卜素、dl-α-生育酚、 L-抗坏血酸钠、烟酰胺、玉米粉、燕麦粉、胡萝卜粉、菠菜粉、薄荷、荷叶、槐米、菊花、山楂、桑叶、青钱柳叶、左旋肉碱、燕麦β-葡聚糖。
本发明的第二个目的是提供一种上述降血压专用型临床营养配方的制备方法方法，其包括如下步骤：称取预定量的各原料，其中维生素、微量元素和常量元素、药食同源成分和新资源食品原料预先制备成预混料；将预混料和2％麦芽糊精先混合5～15分钟；将其它原料按照逐级递增的原则加入进行混合，混合 10～30分钟，出料，分装。
进一步地，上述各原料均为粒径为50～200μm的粉末形式的原料，配置前及配置完成后均经过杀菌处理。
进一步地，所述营养配方的剂型包括营养粉、营养乳剂、胶囊剂、片剂、丸剂、口服液等。
与现有技术相比，本发明具有以下有益效果：
本发明补充适量高生物价优质蛋白质，优质蛋白质对血浆胆固醇水平有显著地降低作用，全面均衡地补充人体所需的8种必须氨基酸，且奶制品还能降低血小板凝结核胰岛素抵抗。
本发明适度补充脂肪，因为高血压患者脂类代谢异常，常有甘油三酯、总胆固醇、低密度脂蛋白水平升高，共同作用于血管内皮功能导致动脉粥样硬化的发生。因此在本发明所述的营养配方中减少膳食脂肪，因饱和脂肪酸和血压呈正相关，增加多不饱和脂肪酸，改善脂代谢，减少血管紧张肽原酶依赖性高血压的发生，不饱和脂肪酸n-6：n-3＝4～6：1。橄榄油不饱和脂肪酸含量达90％，紫苏油不饱和脂肪酸含量达95％，其中α-亚麻酸含量高达50-70％左右。
本发明添加了膳食纤维，其能影响胃肠道功能并间接影响胰岛素代谢，减少脂肪吸收，减轻体重，间接辅助降压。干预研究表明平均补充14g膳食纤维，收缩压和舒张压降低约1.6/2.0mmHg。
本发明适度的添加钠，因为过多摄入钠引起血压升高的机制是血液中的钠增多,保留水分也多，血容量加大，心脏负担加重，高流量血液对血管壁的压力加大，易损伤血管内膜；过多钠使血管内皮细胞内水分增加，引起血管壁肿胀，管腔变小，血流阻力加大；过多钠可改变血压昼高夜低的规律，是老年高血压发生脑卒中的危险因素。一些干预试验证实，钠摄入量每降低100mmol/d，高血压者的收缩压下降5.8mmHg，舒张压下降2.5mmHg；血压正常者，收缩压和舒张压各下降2.3/1.4mmHg。
本发明还可适度的添加钾，其针对不同类型的高血压的作用机理是一致的。钾通过直接扩张血管作用，以及尿钠排出作用而降低血压。
本发明适度的添加钙，低含量的血钙指数会直接强化血清细胞膜对于钙离子的通透作用，从而造成血钙的跨膜内流，最终导致血管剧烈收缩，血压急剧上升。补充钙可有效舒张血管，缓解平滑肌的兴奋性，减轻血管压力。并适度的添加锌，锌参与激素和维生素的合成，是肾上腺素的固有成分和功能单位。锌能激活血管紧张素转换酶的活性，参与血压的调节。
本发明还添加维生素C和维生素E，维生素C通过直接参与体内氧化还原及羟化反应清除氧自由基，抑制动脉内皮细胞产生脂质过氧物，促进前列环素2 合成，抑制血小板黏附聚集，提高NO的生成及利用，提高NO合酶活性，改善内皮功能。维生素C能预防缺血再灌注的血管损伤，改善原发性高血压患者的动脉硬化及血管内皮功能。维生素E能改善血脂代谢异常，防止氧自由基对内皮细胞的损伤，减少血细胞沉积。
本发明配方中所含的叶酸与维生素B6、B12联合应用，可降低血同型半胱氨酸水平。血同型半胱氨酸水平明显升高，可诊断“高同型半胱氨酸血症”，它是卒中等心脑血管病的的危险因素，尤其是还伴有高血压病史。同时血同型半胱氨酸还是动脉粥样硬化的主要危险因子，并可引发多种疾病。
本发明配方中所含的左旋肉碱可通过促进脂肪酸进入线粒体氧化分解，提高血液中低密度脂蛋白水平进而改善高血压的临床症状。左旋肉碱来源于左旋肉碱、左旋肉碱酒石酸盐中的一种或多种组合。
本发明配方中额外添加的γ－氨基丁酸为中枢神经系统中抑制神经递质的物质之一，在调理心血管生理功能中起重要调节作用。它通过调节中枢神经系统，作用于脊髓的血管运动中枢，与突触后由抗扩张血管作用的γ-氨基丁酸A型受体和对交感神经末梢有突触前抑制作用的γ-氨基丁酸B型受体结合，有效促进血管扩张，从而达到降低血压的目的。
本发明所述的营养配方还同时配伍多种药食同源成分、新食品原料、膳食精华，辅助降低血压。
本发明通过选用合理的基础营养素，基于高血压患者的营养摄入，对各组分的配比进行适应性调整，同时添加具有降血压、增强抵抗力等功效的药食同源成分、膳食精华和新资源食品等特殊营养素，改善高血压患者营养结构，辅助改善高血压患者的血压状态及机体健康状况，实现降低血压的目的。
具体实施方式
本发明提供一种降血压专用型临床营养配方，包括如下组分及其重量份数：蛋白质14-35份、脂肪2-9份、碳水化合物50-60份、膳食纤维4-10份、牛磺酸 0.05-0.14份、钠0.10-0.16份、磷0.1-0.3份、镁0.08-0.3份、钙0.3-0.5份、铁 0.008-0.02份、锌0.005-0.01份、β-胡萝卜素0.005-0.04份、维生素E 0.005-0.04 份、维生素C 0.05-0.4份、烟酰0.005-0.04份、左旋肉碱0.4-0.8份、燕麦β-葡聚糖0.1-0.8份、膳食精华1～3.5份、药食同源成分0.5～2份和新食品原料0.05-0.3 份。
下面结合实施例，对本发明的具体实施方式作进一步描述。以下实施例仅用于更加清楚地说明本发明的技术方案，而不能以此来限制本发明的保护范围。
实施例1
本发明所述的降血压专用型临床营养配方每100g包括以下组分：
制备方法：按照组分表称量各组分，其中维生素、矿物质、药食同源和新资源食品原料按照表格先制备成制备预混料；将复合维生素、复合矿物质、药食同源、新资源食品原料和2％麦芽糊精先混合10分钟；然后将其它物料按照逐级递增的原则投入混合机，混合20分钟，出料，称重记录，分装。
实施例2
本发明所述的降血压专用型临床营养配方每100g包括以下组分：
制备方法：按照组分表称量各组分，其中维生素、矿物质、药食同源和新资源食品原料按照表格先制备成制备预混料；将复合维生素、复合矿物质、药食同源、新资源食品原料和2％麦芽糊精先混合10分钟；然后将其它物料按照逐级递增的原则投入混合机，混合20分钟，出料，称重记录，分装。
实施例3
本发明所述的降血压专用型临床营养配方每100g包括以下组分：
制备方法：按照组分表称量各组分，其中维生素、矿物质、药食同源和新资源食品原料按照表格先制备成制备预混料；将复合维生素、复合矿物质、药食同源、新资源食品原料和2％麦芽糊精先混合10分钟；然后将其它物料按照逐级递增的原则投入混合机，混合20分钟，出料，称重记录，分装。
应用实施例1
本实施例采用实施例1制备的营养粉对60名高血压患者进行试验，按每人血压水平平均分为3组。
试验方法：选取上述实施例1制备的营养粉，每次15mg，以90ml温水冲泡，每日3次，连续食用3个月。
试验结果如下：
由上可知，本发明所述的降血压专用型临床营养配方能够有效地降低高雪阳并将血压维持在正常水平。
以上对本发明的具体实施例进行了详细描述，但其只作为范例，本发明并不限制于以上描述的具体实施例。对于本领域技术人员而言，任何对本发明进行的等同修改和替代也都在本发明的范畴之中。因此，在不脱离本发明的精神和范围下所作的均等变换和修改，都应涵盖在本发明的范围内。
Claims (10)
1.一种降血压专用型临床营养配方，其特征在于，包括如下组分及其重量份数：蛋白质14-35份、脂肪2-9份、碳水化合物50-60份、膳食纤维4-10份、牛磺酸0.05-0.14份、钠0.10-0.16份、磷0.1-0.3份、镁0.08-0.3份、钙0.3-0.5份、铁0.008-0.02份、锌0.005-0.01份、β-胡萝卜素0.005-0.04份、维生素E 0.005-0.04份、维生素C 0.05-0.4份、烟酰0.005-0.04份、左旋肉碱0.4-0.8份、燕麦β-葡聚糖0.1-0.8份、膳食精华1～3.5份、药食同源成分0.5～2份和新食品原料0.05-0.3份；
其中，所述膳食精华包括玉米粉、燕麦粉、胡萝卜粉、菠菜粉；所述药食同源成分包括薄荷、荷叶、槐米、菊花、山楂、桑叶；所述新食品原料包括青钱柳叶。
2.根据权利要求1所述的一种降血压专用型临床营养配方，其特征在于，所述蛋白质包括水解乳清蛋白粉、浓缩乳清蛋白粉、大豆分离蛋白、全蛋粉、牛初乳、全脂奶粉、白蛋白肽、大豆肽、海洋鱼低聚肽、小麦低聚肽、玉米低聚肽粉、α-乳清蛋白粉、乳铁蛋白中的至少一种。
3.根据权利要求1所述的一种降血压专用型临床营养配方，其特征在于，所述脂肪包括橄榄油微囊粉、紫苏油微囊粉、二十二碳六烯酸油脂、花生四烯酸油脂、鱼油微囊粉、亚麻籽油微囊粉、中链甘油三酯粉、大豆油微囊粉、玉米胚芽油微囊粉、菜籽油微囊粉、核桃油微囊粉、茶油微囊粉、葵花籽油微囊粉中的至少一种。
4.根据权利要求1所述的一种降血压专用型临床营养配方，其特征在于，所述膳食纤维包括菊粉、聚葡萄糖、低聚半乳糖、低聚果糖、低聚木糖、低聚异麦芽糖、抗性糊精、大豆纤维中的至少一种。
5.根据权利要求1所述的一种降血压专用型临床营养配方，其特征在于，所述钙选自碳酸钙、葡萄糖酸钙、柠檬酸钙、乳酸钙、L-乳酸钙、磷酸氢钙、磷酸钙中的至少一种；所述锌选自葡萄糖酸锌、氧化锌、柠檬酸锌中的至少一种。
6.根据权利要求1所述的一种降血压专用型临床营养配方，其特征在于，所述维生素C选自L-抗坏血酸、L-抗坏血酸钠中的至少一种；所述维生素E选自d-α-生育酚、dl-α-生育酚、d-α-醋酸生育酚和dl-α-醋酸生育酚中的至少一种。
7.根据权利要求1所述的一种降血压专用型临床营养配方，其特征在于，所述脂肪中，不饱和脂肪酸n-6：n-3＝4～6：1。
8.根据权利要求1所述的一种降血压专用型临床营养配方，其特征在于，所述营养配方为肠内营养制剂，每100g的总能量为1400-1800kJ。
9.根据权利要求1所述的一种降血压专用型临床营养配方，其特征在于，所述营养配方包括乳清蛋白、大豆分离蛋白、全脂奶粉、全蛋粉、牛初乳、牛磺酸、紫苏油、橄榄油、冰糖、麦芽糊精、木薯淀粉、菊粉、低聚半乳糖、低聚异麦芽糖、抗性糊精、大豆纤维、柠檬酸钙、L-乳酸钙、磷酸氢钙、柠檬酸钠、硫酸镁、葡萄糖酸亚铁、葡萄糖酸锌、β-胡萝卜素、dl-α-生育酚、L-抗坏血酸钠、烟酰胺、玉米粉、燕麦粉、胡萝卜粉、菠菜粉、薄荷、荷叶、槐米、菊花、山楂、桑叶、青钱柳叶、左旋肉碱、燕麦β-葡聚糖。
10.一种如权利要求1～9中任一项所述的降血压专用型临床营养配方的制备方法，其特征在于，包括如下步骤：称取预定量的各原料，其中维生素、微量元素和常量元素、药食同源成分和新资源食品原料预先制备成预混料；将预混料和2％麦芽糊精先混合5～15分钟；将其它原料按照逐级递增的原则加入进行混合，混合10～30分钟，出料，分装。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910267304.7A CN109965270A (zh) | 2019-04-03 | 2019-04-03 | 一种降血压专用型临床营养配方及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910267304.7A CN109965270A (zh) | 2019-04-03 | 2019-04-03 | 一种降血压专用型临床营养配方及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109965270A true CN109965270A (zh) | 2019-07-05 |
Family
ID=67082793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910267304.7A Withdrawn CN109965270A (zh) | 2019-04-03 | 2019-04-03 | 一种降血压专用型临床营养配方及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109965270A (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110731501A (zh) * | 2019-11-07 | 2020-01-31 | 上海复旦奥医医学科技有限公司 | 一种子宫肌瘤专用型临床营养配方及其制备方法 |
| CN110754656A (zh) * | 2019-11-07 | 2020-02-07 | 上海奥医高科技实业有限公司 | 一种淋巴肿瘤功能专用型临床营养配方及其制备方法 |
| CN114128890A (zh) * | 2021-12-10 | 2022-03-04 | 黑龙江飞鹤乳业有限公司 | 营养补充性组合物 |
| CN114831183A (zh) * | 2022-05-12 | 2022-08-02 | 甘南倍益特生物科技有限公司 | 一种抗高原反应配方奶粉及其制备方法 |
| CN114868891A (zh) * | 2022-03-26 | 2022-08-09 | 大医声科技(北京)有限公司 | 一种适用心脑血管患者营养素配方 |
| CN115053959A (zh) * | 2022-07-05 | 2022-09-16 | 三奇生物医药(山东)有限公司 | 基于血脂异常患者的特殊膳食用食品及其制备方法 |
-
2019
- 2019-04-03 CN CN201910267304.7A patent/CN109965270A/zh not_active Withdrawn
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110731501A (zh) * | 2019-11-07 | 2020-01-31 | 上海复旦奥医医学科技有限公司 | 一种子宫肌瘤专用型临床营养配方及其制备方法 |
| CN110754656A (zh) * | 2019-11-07 | 2020-02-07 | 上海奥医高科技实业有限公司 | 一种淋巴肿瘤功能专用型临床营养配方及其制备方法 |
| CN114128890A (zh) * | 2021-12-10 | 2022-03-04 | 黑龙江飞鹤乳业有限公司 | 营养补充性组合物 |
| CN114868891A (zh) * | 2022-03-26 | 2022-08-09 | 大医声科技(北京)有限公司 | 一种适用心脑血管患者营养素配方 |
| CN114831183A (zh) * | 2022-05-12 | 2022-08-02 | 甘南倍益特生物科技有限公司 | 一种抗高原反应配方奶粉及其制备方法 |
| CN115053959A (zh) * | 2022-07-05 | 2022-09-16 | 三奇生物医药(山东)有限公司 | 基于血脂异常患者的特殊膳食用食品及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109965270A (zh) | 一种降血压专用型临床营养配方及其制备方法 | |
| US6326031B1 (en) | Method of decreasing cholesterol and triglycerides levels with a composition containing fish oil, garlic, rutin, and capsaicin | |
| TWI359021B (en) | Nutritional composition for controlling blood suga | |
| US5629023A (en) | Medical food composition for metabolic detoxification | |
| US20020187204A1 (en) | Diet composition and method of weight management | |
| JPWO2006033349A1 (ja) | 総合経腸栄養組成物 | |
| CN101715913B (zh) | 一种调节血脂的胶囊及其生产制作工艺 | |
| KR20080108523A (ko) | 지방 축적 억제제 | |
| CN102578307A (zh) | 一种双亚高端植物油及其制备方法 | |
| CN105982071A (zh) | 高剂量维生素d3口服制剂配方 | |
| CN110742267B (zh) | 一种炎性肠病全营养配方食品 | |
| KR20090087671A (ko) | 두충을 이용한 고혈압 억제 음료 개발 | |
| CN105166901B (zh) | 一种透析患者用营养组合物 | |
| CN110538315B (zh) | 一种具有防治透析患者并发症功效的组合物及其制备方法和其应用 | |
| JPWO2018179441A1 (ja) | インスリン抵抗性の悪化予防または改善剤 | |
| CN112690453A (zh) | 一种组合物、复合油及其应用 | |
| JPH05336923A (ja) | 炭水化物および脂質の代謝を制御するためのクロムおよびビタミンｅ、ｃを含んだ調製品の使用 | |
| WO2015098474A1 (ja) | 米タンパク質を有効成分とする血清尿酸低下剤 | |
| CN101229218B (zh) | 用于治疗糖尿病的钒复方组合物及其制造方法 | |
| AU6282796A (en) | Fish oil and garlic nutritive composition | |
| CN113812552B (zh) | 一种全营养固体饮料 | |
| KR101147913B1 (ko) | 혈당 조절용 조성물 | |
| Sardar et al. | Effect of exercise with and without pomegranate concentrate consumption on HbA1c and C-peptide levels: a study of middle-aged women with metabolic syndrome | |
| Broadhurst et al. | Evening primrose oil: pharmacological and clinical applications | |
| CN109757582A (zh) | 改善良性前列腺增生症状的营养食品配方 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190705 |